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In an environment where cost, timeliness, and quality drives the
business, it is essential to look for answers in technology where
these challenges can be met. In the Novartis Pharmaceutical
Quality Assurance Department, automation and robotics have
become just the tools to meet these challenges. Although automation
is a relatively new concept in our department, we have fully
embraced it within just a few years. As our company went through
a merger, there was a signi￿ cant reduction in the workforce within
the Quality Assurance Department through voluntary and invo-
luntary separations. However the workload remained constant or in
some cases actually increased. So even with reduction in laboratory
personnel, we were challenged internally and from the headquarters
in Basle to improve productivity while maintaining integrity in
quality testing. Benchmark studies indicated the Su¶ ern site to be
the choice manufacturing site above other facilities. This is
attributed to the Su¶ ern facility employees’ commitment to reduce
cycle time, improve eµ ciency, and maintain high level of regulatory
compliance. One of the stronger contributing factors was automa-
tion technology in the laboratoriess, and this technology will
continue to help the site’s status in the future. The Automation
Group was originally formed about 2 years ago to meet the
demands of high quality assurance testing throughput needs and
to bring our testing group up to standard with the industry.
Automation began with only two people in the group and now
we have three people who are the next generation automation
scientists. Even with such a small sta¶ , we have made great strides
in laboratory automation as we have worked extensively with each
piece of equipment brought in. The implementation process of each
project was often diµ cult because the second generation automation
group came from the laboratory and without much automation
experience. However, with the involvement from the users at `get–
go’, we were able to successfully bring in many automation
technologies. Our ￿ rst experience with automation was SFA/
SDAS, and then Zymark TPWII followed by Zymark Multi-
dose. The future of product testing lies in automation, and we shall
continue to explore the possibilities of improving the testing
methodologies so that the chemists will be less burdened with
repetitive and mundane daily tasks and be more focused on bringing
quality into our products.
Introduction
When we hear the word ` Automation’ , a mixture of
emotions can be evoked, initially bringing fear. It is quite
understandable that a person unexposed to any type of
automation technology can dramatically fear the un-
knownÐ scenes ¯ ashing through one’ s mind from a movie
of a robotic monster wreaking havoc upon mankind,
thoughts of the starving family of a worker whose job is
replaced by a robot that chugs along in an assembly line,
and so on. However, as we come to our senses and begin
to look around, we realize the signi® cant impact of
automation and how it has improved our lives. If we
take the de® nition of ` automation’ from Webster’ s dic-
tionary, it simply means ` the technique of making an
apparatus, a process, or a system operate automatically’ .
So in reality, we live in an age of automation, unable to
imagine living without the bene® ts of co¶ ee makers,
washers and dryers, and VCRs.
When we recognize the truth about the positive in¯ uence
of automation technology in our daily lives, the fear of
laboratory automation can easily be dissolved and a sense
of excitement takes over. The vision of automation bring-
ing relief to chemists from mundane and repetitive tasks
and increasing productivity and eµ ciency thereby con-
tributing to the overall success of the company can now
be a reality. This paper, though in many parts non-
technical, is critical in the understanding of how we can
bring new automation technology to an environment
speci® c to quality assurance (QA) in pharmaceutical
industries by breaking the ` invisible yet very real barrier’
between fear and excitement. A great technology is only
great to the degree it is understood and accepted by its
users, so this paper will deal with challenges surrounding
both people and related technical issues.
History of automation at Novartis
Although the big push for automation in QA laboratories
is recent, the term is certainly not new at Novartis.
During the pre-merger era, many of the ® nished products
in tablet form were tested for content uniformity with
` Technicon SolidPrep and Autoanalyzers’ . It was some-
what of a predecessor to TPWII Workstation in that
both systems utilized the homogenizer chamberÐ al-
though the former lacked computer-generated operation.
However, the diµ culty with Technicon Autoanalyzers
was in troubleshooting the numerous reagent lines and
glass loops that introduced the required chemical
reactions through a peristaltic pump system.
Another automation technology during that time was
an on-line multibath dissolution unit for applications
speci® c to patches, transdermal systems, and extended
release tablets. The unit was a semi-automated system for
dissolution pro® les which pulled samples at designated
time-points to a HP8452 spectrophotometer for reading,
calculation, and generation of reports. The next genera-
tion of dissolution solution would follow much later with
the Zymark Multidose System that completely auto-
mated dissolution from media dispensing all the way to
report generation.
These two systems are just some examples of how
automation began to play a signi® cant role in the
eµ cient processing of samples in the laboratories. Then
the merger occurred between Ciba-Geigy and Sandoz,
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called Novartis.
Post-merger challenges
The merger and therefore the creation of Novartis
resulted in challenges that had to be addressed almost
immediately. These challenges included reducing the
workforce, cutting costs, increasing productivity, trans-
ferring products from other sites, and benchmarking the
Su¶ ern site as the premier manufacturing site. As these
challenges surfaced, the Quality Assurance Department
(functioning under Technical Operations) responded
quickly. One of the responses was the formation of an
Automation Support Group to bring in systems that
would increase eµ ciency and productivity and therefore
drastically cut costs for the laboratory operations.
The greatest diµ culty in bringing new automated
systems into the laboratoriess was being able to sell the
idea of automation bene® ts to the user community, who,
by in large, had little interest or awareness about auto-
mation. This brought a negative ` domino’ e¶ ect to the
evaluation and the implementation of new automation
technology. This was evident in the overall process of
qualifying a content uniformity workstation from Source
for Automation, Inc. The unit from Source for Automa-
tion, known as a Solid Dosage Assay System (SDAS), was
met with resistance from the laboraty sta¶ from the
beginning. People were so used to doing everything
manually that they showed a lack of support and co-
operation when the system came into the laboratory. The
result was a long and arduous implementation process. A
similar path was observed for the implementation of the
Zymark Multidose Automated Dissolution System.
Overcoming the biggest challenge
Of all the challenges, the issues related to the user
community, comprised primarily of laboratory bench
chemists, were of greatest concern. The question was
` how could people be motivated to receive and utilize
automation technology with enthusiasm?’ It is very
diµ cult when people resist changes and when their old
habits just will not die. The key was to bring awareness
and knowledge about automation to the laboratory
people so the interest and the initiative would be from
them. They needed to know that automation is about
working smarter, increasing productivity and staying
competitive, and freeing up time for other thinking tasks.
To do this required an informational presentation. This
was accomplished through a half-day seminar sponsored
by Novartis and Zymark.
Laboratory management and representative chemists
from each product group were invited and the seminar
proved to be successful. The audience ® rst received an
overview of how automation can bring short-term and
long-term bene® ts without necessarily reducing the head-
count. Following the overview was a presentation by
Zymark speci® c to their products so the audience could
make a connection between theory and practice. The
response after the seminar was tremendously positive.
There were a lot of questions based on interest, and the
participants began already to speak of possible automa-
tion needs and showed desire to be actively involved.
Following this event and initiation of several automation
projects, a step was taken to establish an ` Automation
Partnership’ between the Automation Support Group
and the QA testing groups. This is illustrated by a ¯ ow
chart in ® gure 1 which shows the assignment of respon-
sibilities. The chart displays the importance of each
group’ s involvement in successfully implementing a
system from evaluation to ® nal implementation and
training on the automated system. The highlighted box
indicates an extensive involvement required from the user
group in completing the studies necessary for speci® c
method needs. ` QA’ identi® es the testing group personnel
whereas ` A’ identi® es the automation group personnel.
Figure 1. Assignment of responsibilities. QA, testing group
personnel; A, automation group personnel.
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when a user from the testing group is involved from the
initial phase of the project, he/she is more likely to take
ownership of the instrument and participate not only in
the implementation of the instrument but in its main-
tenance as well. When the users are motivated from the
beginning, the rate of success in implementation increases
drastically. As a user (a bench chemist) is invited to visit
possible vendors and as the user has some say in the
evaluation and the purchase of an automated system,
there will be a higher level of commitment for utilization.
Table 1 is an example of a chart that may be introduced
to the users so di¶ erent activities and expectations are
de® ned clearly before the start of a project. This can be
one of many ways to motivate and encourage the user in
their involvement with automation projects.
Personal experiences with automation implemen-
tation
When 1999 began, four di¶ erent projects were already
either in process or being initiated as a result of joint
evaluation e¶ ort by the testing and the automation
group. The decision came from management to apply
automation to high volume products and to tests such as
content uniformity and dissolution. Obstacles came from,
® rst, the fact that the new year brought changes in the
automation group with a complete turnover of the sta¶ .
Even though the automation team was already in place,
the changeover in the members meant a new beginning,
having to retrace the steps in the project to the ® rst stage.
At this point the commitment was already made to
complete some of the projects on time and under budget.
The projects started by the old members of the automa-
tion group had to be re-evaluated and user support
brought in where required.
As projects progressed, we as automation support group
members faced other barriers. Many of the problems
dealt with system validation issues and execution of
plans (outlined in table 2). These problems were system-
atically resolved as they surfaced and gave us a good
picture of how upcoming projects can be anticipated and
handled. Figure 2 shows a diagram of a ` Project Life
Cycle’ showing how everything begins with motivation
and goes around, coming back to motivation. The dia-
gram also shows how the success of each segment is
crucial in the next step of the circle. We have adopted
this approach because it is a step-by-step approach
constantly fuelled by motivation. The motivation on
the automation and the user team will keep the project
moving even as we face on-going challenges.
Table 1. Responsibility chart.
Tasks Project Manager Validation Group Lead QC Group Lead Super User-QC Scientist Deadline
ME protocol A P A
Shipment installation P
Validation IQ, OQ, PQ P S
Validation report A P A
ME Testing S P
ME reports A P A
Change control A P A
Training P S
Launch
A, Approver; P, Primary Responsible Person; S, Secondary Responsible Person.
Table 2. System validation issues and execution of plans.
System validation issues Execution of plans
Vendor audit requirement as per Novartis Quality Module 5.2 Calibration procedure requirement
Protocol approval by Computer System Validation Committee SOP requirement to cover method equivalency testing
Stress test requirement Change control documents
Function risk assessment Operating procedure requirement
Y2K issues General test requirement (GT)
Figure 2. Projected life cycle.
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As the automation projects were completed, everyone
began to see the bene® ts gained through the implementa-
tion of these systems. The di¶ erence between the manual
and the automated methods was evident with increases
not only in eµ ciency but in quality as well. Looking at
the examples of implementing speci® cally Zymark’ s
TPWII Content Uniformity Workstation and Multidose
Automated Dissolution System, the bene® ts are clear.
With TPWII, there is no more tedious pipetting, saving
time and glassware, especially for content uniformity
testing. This gives chemists more time for validating
reports and other thinking tasks thereby contributing to
faster sample turnaround time. The automated method is
superior to the manual method which is tedious, time
consuming, wastes manpower and glassware, exposes
harmful chemicals, and adds to testing errors.
Looking at the bene® ts of the Multidose Automated
Dissolution System, one can easily see how the ¯ exibility
plus the eµ ciency of the system gives signi® cant gains for
the testing of products. Some of the observable advan-
tages of the system include: rapid and accurate vessel
® lling with selected media, accurate temperature mon-
itoring, single and multipoint dissolution, eµ cient and
rapid vessel cleaning, up to 8 batches per setup, and
interfacing capability to HPLC, UV/Vis, or a fraction
collector. In addition, the automated systems bring cost
savings that can be quantitatively measured. The pro-
jected savings for Zymark Multidose Plus can be seen in
table 3. Table 4 shows additional examples of cost savings
for a di¶ erent type of automated dissolution system. Each
table indicates a speci® c example of product testing.
The future of automation at Novartis
In order to stay competitive in the pharmaceutical
industry, it is necessary to pursue excellence in every
possible facet of cost, timeliness, and quality. Automation
of testing processes in the laboratory is a vital means of
achieving success in those areas. So as we look to the
future of automation at Novartis, our sights are on
globalization of automation for Basle and various sites
in US including East Hanover (NJ), Su¶ ern (NY),
Lincoln (NE), and Broom® eld (CO). This would
facilitate the transfer of method for a product. We would
be able to send a method on a ¯ oppy disc or even
electronically to the receiving site with minimal testing
required.
As we press on with the future of automation in the QA
environment, together as testing and automation groups,
we shall be more proactive and not reactive in assessing
the needs in the laboratory and in ® nding appropriate
solutionsÐ solutions that not only bring increases in
productivity and cost savings but also bring the working
relationships of the automation and the user groups to a
whole new level. We can never underestimate the e¶ ort
in automating a process in the QA laboratories; however,
with proper planning and preparation supported by
insight through prior technical knowledge, the future of
automation is secure at Novartis.
Trademarks
Source for Automation, Inc (SDAS)
Zymark (TPWII, Multidose, Multidose Plus)
Technicon (Solidprep, Autoanalyzers)
Hewlett Packard (HP8452)
Novartis Pharmaceuticals Corporation (Quality Module
5.2)
Table 3. Projected savings on Diovan capsules (a transfer product) using Multidose Plus.
Activity Yearly saving
Reduction in standard hours $58875.00
Increased testing capacity $25200.00
Use of the instrument for additional product $22125.00
Total potential savings/year $106 200.00
Table 4. Projected savings on Tegretol XR tablets using Distek/ HP8453 system.
Activity Yearly Saving
Transfer two second shift analysts back to ® rst shift $16 500.00
Increased testing capacity $9600.00
Reduction in standard hours $18000.00
Flexibility to begin test at any time of the day $9600.00
Use of the instrument for additional product $7000.00
Total potential savings/year $60 700.00
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